Hyperpolarized [1-13C]-pyruvate MRS evaluates immune potential and predicts response to radiotherapy in cervical cancer

Gigin Lin*, Ching Yi Hsieh, Ying Chieh Lai, Chun Chieh Wang, Yenpo Lin, Kuan Ying Lu, Wen Yen Chai, Albert P. Chen, Tzu Chen Yen, Shu Hang Ng, Chyong Huey Lai

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

2 Scopus citations

Abstract

BACKGROUND: Monitoring pyruvate metabolism in the spleen is important for assessing immune activity and achieving successful radiotherapy for cervical cancer due to the significance of the abscopal effect. We aimed to explore the feasibility of utilizing hyperpolarized (HP) [1- 13C]-pyruvate magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) to evaluate pyruvate metabolism in the human spleen, with the aim of identifying potential candidates for radiotherapy in cervical cancer.

METHODS: This prospective study recruited six female patients with cervical cancer (median age 55 years; range 39-60) evaluated using HP [1- 13C]-pyruvate MRI/MRS at baseline and 2 weeks after radiotherapy. Proton ( 1H) diffusion-weighted MRI was performed in parallel to estimate splenic cellularity. The primary outcome was defined as tumor response to radiotherapy. The Student t-test was used for comparing 13C data between the groups.

RESULTS: The splenic HP [1- 13C]-lactate-to-total carbon (tC) ratio was 5.6-fold lower in the responders than in the non-responders at baseline (p = 0.009). The splenic [1- 13C]-lactate-to-tC ratio revealed a 1.7-fold increase (p = 0.415) and the splenic [1- 13C]-alanine-to-tC ratio revealed a 1.8-fold increase after radiotherapy (p = 0.482). The blood leukocyte differential count revealed an increased proportion of neutrophils two weeks following treatment, indicating enhanced immune activity (p = 0.013). The splenic apparent diffusion coefficient values between the groups were not significantly different.

CONCLUSIONS: This exploratory study revealed the feasibility of HP [1- 13C]-pyruvate MRS of the spleen for evaluating baseline immune potential, which was associated with clinical outcomes of cervical cancer after radiotherapy.

TRIAL REGISTRATION: ClinicalTrials.gov NCT04951921 , registered 7 July 2021.

RELEVANCE STATEMENT: This prospective study revealed the feasibility of using HP 13C MRI/MRS for assessing pyruvate metabolism of the spleen to evaluate the patients' immune potential that is associated with radiotherapeutic clinical outcomes in cervical cancer.

KEY POINTS: • Effective radiotherapy induces abscopal effect via altering immune metabolism. • Hyperpolarized 13C MRS evaluates patients' immune potential non-invasively. • Pyruvate-to-lactate conversion in the spleen is elevated following radiotherapy.

Original languageEnglish
Article number46
Pages (from-to)46
JournalEuropean Radiology Experimental
Volume8
Issue number1
DOIs
StatePublished - 10 04 2024

Bibliographical note

© 2024. The Author(s).

Keywords

  • Carbon-13
  • Magnetic resonance spectroscopy
  • Radiotherapy
  • Spleen
  • Uterine cervical neoplasms
  • Prospective Studies
  • Humans
  • Middle Aged
  • Carbon-13 Magnetic Resonance Spectroscopy/methods
  • Lactates
  • Uterine Cervical Neoplasms/diagnostic imaging
  • Female
  • Pyruvic Acid/metabolism

Fingerprint

Dive into the research topics of 'Hyperpolarized [1-13C]-pyruvate MRS evaluates immune potential and predicts response to radiotherapy in cervical cancer'. Together they form a unique fingerprint.

Cite this